DEVELOPMENT OF FLOATING GASTRORETENTIVE DRUG DELIVERY SYSTEM BASED ON A NOVEL EXCIPIENT FOR METFORMIN HYDROCHLORIDE USING MIXTURE DESIGN by PAWAR, RAJESH et al.
 
Original Article 
DEVELOPMENT OF FLOATING GASTRORETENTIVE DRUG DELIVERY SYSTEM BASED ON A 
NOVEL EXCIPIENT FOR METFORMIN HYDROCHLORIDE USING MIXTURE DESIGN 
 
RAJESH PAWAR1*, SWATI JAGDALE2, DHEERAJ RANDIVE3 
1MAEER’s Maharashtra Institute of Pharmacy, MIT Campus, Kothrud, Pune, India. 2School of Pharmacy, Dr. Vishwanath Karad MIT World 
Peace University, MIT Campus, Kothrud, Pune, India, 3Rajarambapu College of Pharmacy, Sangli, India 
Email: rajesh.pawarmit@yahoo.com 
Received: 08 Jun 2020, Revised and Accepted: 27 Aug 2020 
ABSTRACT 
Objective: The present study aimed to develop a new SR metformin hydrochloride (MH) gastroretentive formulation with novel excipient (NE), 
which has better floatation and can be prepared with more simple pharmaceutical techniques for the treatment of diabetes Mellitus. 
Methods: A gastro-retentive floating matrix tablet (GFT) formulation of MH was prepared using various concentrations of PEO (Polyox WSR-303) 
and hydroxypropyl methylcellulose K100M (HPMC K100 M) and Floating agent (novel excipient) to achieve desirable TFT, FLT and drug release. 
The wet granulation method was selected using isopropyl alcohol as a binder for the preparation of tablets. D-optimal non-simplex mixture design 
was used for the selection of suitable polymer concentrations and floating agents. Release kinetics was used to determine the mechanism of drug 
release. 
Results: It was observed that GFT with optimum quantities of PEO, HPMC K100M, and the floating agent showed 100 % of drug release in 24h with 
FT up to 24h and minimum FLT of less than 2 min. Formulation with an in vitro release profile slower to the marketed sample was prepared. 
Conclusion: A sustained-release (GFT) of MH tablets using PEO, HPMC K100M, and an effervescent system was successfully prepared. A GFT 
formulation with an in vitro release profile slower to the marketed sample that releases MH for 24h may suitable for once-daily dosing can be 
prepared. 
Keywords: Novel excipient, Drug release, Floating drug delivery system, Mixture design, HPMC, PEO, Total floating time, Floating lag time, FDDS 
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INTRODUCTION 
Oral administration is the most common route for drug delivery due 
to ease of administration and full control of administration by the 
patient, together with a high degree of flexibility on dosing. Floating 
drug delivery system (FDDS) can prolong gastric residence time 
(GRT), resulting in increased absorption of the drug and high 
bioavailability and enhance the solubility of drugs that are less 
soluble in high pH environment. Gastroretention would also 
facilitate local drug delivery to the stomach and proximal small 
intestine. Thus, gastro retention improved therapeutic activity and 
substantial benefits to patients [1-4]. 
In the current study, MH was examined as a model drug, which is a 
disubstituted biguanide and is an orally administered hypoglycemic 
agent [5]. Due to its ability to lower blood glucose levels, it is widely 
used to treat non-insulin-dependent type 2 diabetes mellitus 
(T2DM). It lowers blood glucose concentration and glycosylated 
hemoglobin A1c levels by inhibiting hepatic gluconeogenesis and 
improves the insulin sensitivity of peripheral tissues without 
causing hypoglycemia or weight gain, in contrast to other 
antidiabetic drugs. These pharmacological advantages have made 
MH the first choice for the treatment of T2DM. MH is freely soluble 
in water and its absolute bioavailability is 50 to 60%. This Low 
systemic bioavailability is due to incomplete absorption of MH. The 
absorption site for MH is the proximal part of the small intestine 
where the gastrointestinal absorption is complete after 6 h It is 
poorly absorbed in the stomach, jejunum, and ileum [5]. 
Furthermore, MH requires the administration of two or three daily 
doses to maintain adequate therapeutic concentrations because it 
has low oral bioavailability and short plasma half-life. Nevertheless, 
conventional GFT formulations should not be encouraged because 
the drug absorption is site-dependent in the GIT and more than 30 
% of the administered dose is excreted unchanged in the feces. 
Considering the inverse correlation between medication adherence 
and dosing frequency, a GFT (SR) formulation designed for once-
daily dosing was deemed suitable for MH in terms of improving the 
compliance and gastrointestinal tolerability. To increase the 
bioavailability of MH, it would be beneficial to develop a floating 
gastro-retentive matrix tablet with prolonged gastric retention time 
and gradual drug release of the drug at the absorption site [6, 7]. 
This work shows that the novel excipient-NE (calcium derivative) 
along with other polymers, is a suitable pharmaceutical excipient for 
the FDDS. The NE has recently introduced a porous microparticle with 
a nanostructured, lamellar surface, low apparent density, and shows 
promising properties in the field of oral delivery. Due to its unique 
properties, NE holds promise in the preparation of FDDS [8, 9].  
The present study aimed to develop a new gastro retentive 
formulation with NE and gradual release of MH, which has short FLT 
and good floating and swelling abilities and with close to 100% drug 
release within 24h. Matrix tablets of swellable designs were 
prepared using a combination of polymers and NE by wet 
granulation method. The effect of combining two polymers on 
floating properties and release characteristics of MH was also 
evaluated and the formulation was optimized with the help of 
response surface design (D-optimal non-simplex mixture screening 
design). Also, the formulation to be prepared with a slower release 
profile is suitable to retard the Cmax, increase the Tmax and enhance 
the bioavailability as compared to the faster release profile of the 
marketed product, which releases 90% of the drug in about 10h. In 
particular, an extended-release formulation that releases MH for 24h 
may be suitable for once-daily dosing [10, 11]. 
MATERIALS AND METHODS 
Materials 
MH (gifted from Lupin, Pune) served as the model drug and 
hydroxypropyl methylcellulose (methocelK100 M), microcrystalline 
cellulose, stearyl alcohol (gift sample from Lupin, Pune,). NE and 
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citric acid (gifted from Ipca Labs, Mumbai, India), PEG (polyox™ WSR 
303, The Dow chemical company, Midland, Michigan), for wet-
granulation, isopropyl alcohol (Avantor, India) were used. 
Methods 
Formulation of floating tablets of MH 
After the initial developmental trials, it was observed that the critical 
quality attributes (TFT, FLT, and dissolution) are controlled by the 
type of floating agent, polymer type, and its concentration. So, the 
formulation was selected for DOE studies to optimize the effects of 
variables on formulation and it is decided to use HPMC K100M and 
PEO to formulate an FDDS of MH. Tablets were compressed with 
round flat-faced die punches of 19 mm diameter. All trials were 
taken according to table 2 [12]. 
The required amounts of NE, PEO, HPMC, MCC, citric acid, stearyl 
alcohol, and MH were weighed and mixed in a mortar and pestle for 10 
min. afterward, isopropyl alcohol was added to the mixture to form a 
paste. The obtained slurry was dried and passed through #18sieve and 
dried in a hot air oven at 50◦C for the 90 min; dried granules were 
lubricated with magnesium stearate (sieved through #40 mesh. The 
blended powder was compressed with 200N in hardness [13, 14]. 
Experimental design 
In particular, when the measured response is assumed to depend 
only on the proportions of the ingredients present in the 
formulation, it is possible to use experimental mixture design. In the 
present study, an 11-run D-optimal non-simplex screening mixture 
design was applied to the evaluation of critical quality attributes in a 
complete tablet formulation. Design with 3 levels, 4 factors were 
applied to initial screening and optimize the proposed formulation. 
D-optimal Non-simplex screening mixture design was preferred as 
the choice of experimental design considering its requirement of 
fewer numbers of experimental runs for three or four independent 
variables than full factorial design. Therefore, different formulation 
trials were randomized and presented in below table 2, the 
randomization was provided by the design-expert software (version 
11.0.0, Stat-Ease, Inc., Minneapolis, MN, USA); lower and upper 
limits of pharmaceutical formulation excipients were proposed 
based on literature search, preliminary screening trials and 
provided as design constraints in table 1. independent variables NE 
as a floating agent, PEO and HPMC K100M CR both as release 
modifying polymer and MCC as diluent) were evaluated having 
amount ranging from 400 mg to 600 mg for NE and PEO/HPMC 
having amount ranging from 170 mg to 250 mg and MCC amount 
ranging from 20 mg to 380 mg each inadequate concentration 
ranges, because of their different specific functions in tablet 
production. All other formulations and processing variables were 
kept constant throughout the study and dependent variables (FLT, 
TFT and dissolution at 3h, 10h, and 24h) were pointed out because 
for floating SR tablets a balance for having tablets with short FLT, 
extended floating time and extended dissolution profile is of great 
importance and poses a significant challenge for formulation 
development and optimization. The layout of the experimental 
design is given in Table. Each tablet had 500 mg of MH and fixed 
amounts of citric acid (20 mg), stearyl alcohol (50 mg), and 
magnesium stearate (10 mg) to analyze the effect of independent 
variables on tablet properties. In the present experimental design 4 
factors evaluated at 3 levels with experimental trials being performed 
at all 8 possible combinations with limited experiments and 3 
replications at the center point’s altogether, 11 experimental runs that 
are illustrated in table 2. Other composition and manufacturing 
conditions were kept constant for all experimental runs [15-17]. 
 
Table 1: Experimental range and levels of the independent variables 
Variable Range and level (mg/tab) 
-1 0 +1 
A: NE 400 500 600 
B: PEO 170 210 250 
C: HPMC K100M (HPMC) 170 210 250 
D: Diluent (MCC) 20 200 380 
 
Table 2: MH gastro-floating GFT tablet optimization trials 
Formulation codes  F-9 F-4 F-10 F-5 F-11 F-1 F-8 F-7 F-6 F-2 F-3 
Experimental run order 9 4 10 5 11 1 8 7 6 2 3 
Ingredients ↓ Mg/tablet 
 MH 500 500 500 500 500 500 500 500 500 500 500 
 NE 400 600 400 600 600 400 600 400 500 500 500 
PEO(Polyox™ WSR-303) 170 170 250 250 250 170 170 250 210 210 210 
HPMC K100M  170 170 170 250 170 250 250 250 210 210 210 
Stearyl alcohol 50 50 50 50 50 50 50 50 50 50 50 
Citric acid  20 20 20 20 20 20 20 20 20 20 20 
Microcrystalline cellulose (MCC) 380 180 300 20 100 300 100 220 200 200 200 
Magnesium Stearate 10 10 10 10 10 10 10 10 10 10 10 
Isopropyl alcohol q. s q. s q. s q. s q. s q. s q. s q. s q. s q. s q. s 
Total 1700 1700 1700 1700 1700 1700 1700 1700 1700 1700 1700 
 
Finally, the calculated empirical models were plotted as contour 
diagrams for revealing the optimal formulation [17]. Data 
obtained from the evaluation of tablets were used to generate 
response surface plots. Linear models were used for data fitting. 
The best fit model with a significant p-value was selected for 
statistical analysis.  
For each response, the model suggested by the software was used to 
fit the data and the mathematical equation suggested by the 
software was solved to get the optimal points. A four-factor model 
was used to assess the relationship between the studied variables 
with the FLT, TFT, and dissolution with a linear model for responses. 
Optimization of response factors was performed for minimizing 
the floating lag time FLT while maximizing the floating time and 
desired dissolution profile. The solution provided by the software 
with the greatest desirability was chosen as the optimum 
condition [18, 19]. 
All responses were fitted to linear models, which were statistically 
validated by performing an analysis of variance (ANOVA). The 
statistical parameters used in evaluating and selecting the best-fitted 
model were the p-value of the model, lack-of-fit test p-value, 
coefficient of determination (R2), adjusted R2, predicted R2, adequate 
precision, and predicted residual sum of squares (PRESS) [20]. 
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Table 3: D-optimal non-simplex screening design for buoyant tablets containing MH 




 HPMC-methocel K100M CR (mg) 
X3 
MCC-microcrystalline cellulose (mg) 
X4 
F-1 400 170 250 300 
F-2 500 210 210 200 
F-3 500 210 210 200 
F-4 600 170 170 180 
F-5 600 250 250 20 
F-6 500 210 210 200 
F-7 400 250 250 220 
F-8 600 170 250 100 
F-9 400 170 170 380 
F-10 400 250 170 300 
F-11 600 250 170 100 
 
Selection and characterization of optimized formulation  
The optimized formulation was selected based on responses, 
namely: FLT, (TFT), and in vitro drug release from GFT tablets using 
non-simplex D-optimal mixture design. The optimized formulation 
was then subjected to the following characterization [21-23]. 
Evaluation parameters 
Post compression parameters 
Compressed tablets were also tested for FLT, TFT, and in vitro drug 
release behavior [24, 25].  
In vitro buoyancy studies 
The in vitro floating behavior of the tablets was determined by FLT. 
It is generally assumed that as FLT increases, the tablet may attach 
to the lower part of the stomach and be unable to float, leading to an 
increase in the chances of gastric emptying. Therefore, FLT may be 
an important factor affecting gastric retention time, requiring 
minimization. 
These tests are usually performed in simulated gastric fluid or 0.1N 
HCl maintained at 37◦C, by using a beaker containing 200 ml of 0.1N 
HCl as the dissolution medium. The time between the introduction 
of the dosage form and its buoyancy in 0.1N HCl and the time during 
which the dosage form remain buoyant were measured. The total 
duration of time by which the dosage form remains buoyant is called 
TFT [26, 27]. 
In vitro drug release study 
The release of MH from the GR tablets was studied using the USP 
dissolution apparatus I (rotating basket). The dissolution test was 
performed using 900 ml of 0.1Nhydrochloric acid. The temperature 
was maintained at 37±0.5 °C. The rotation speed was 100 RPM. Five 
milliliters were withdrawn at predetermined time intervals of 1, 2, 
3, 4, 6, 8, 10, 12, 16, 20, and 24h from each basket and the medium 
was replenished with 5 ml of fresh dissolution medium each time. 
The samples were filtered and diluted to a suitable concentration 
with 0.1N hydrochloric acid. Samples were analyzed by using 
UV/visible spectroscopy at 232 nm. The percentage of drug release 
was plotted against time to determine the release profiles [28, 29].  
Kinetic modeling of drug release 
The in vitro dissolution of the optimized batch of MH floating tablets 
was carried out. The dissolution profile of optimized batch and the 
marketed formulation was fitted to zero-order, first-order, Higuchi, 
Hixson–Crowell, and Korsmeyer–Peppas models to ascertain the 
kinetic modeling of drug release and the model with the highest 
correlation coefficient was considered to be the best model. The 
reading was then processed for dissolution data using DD Solver V1 
software [30-32] 
Fourier transform infrared spectroscopy (FTIR): interaction 
studies  
The primary objective of this investigation was to identify the drug-
using FTIR spectrophotometer. For FTIR the sample was sent into 
the laboratory and the results presented in results and discussion. 
The IR spectra were recorded for MH and powdered tablets of the 
optimized formulation using KBr pellets (by mixing with KBr) by 
FTIR. The scanning range was 4000 cm-1 to 400 cm-1. IR spectra 
were recorded and compared [33, 34]. 
Comparison of optimized formulation with carbophage XR 500 
mg marketed tablet 
Carbophage XR (Merck specialties Pvt Ltd, India) tablets of 500 mg 
dosage strength, designed to release MH over a 12h period. This 
commercial product is a matrix tablet that contains cellulosic 
polymers and drugs; therefore, the SR matrix controls the drug 
release to give sustained release. In vitro drug release profile of 
developed MH, GFT tablets were compared with the drug release 
profile of marketed formulation tablets under similar experimental 
conditions. The data obtained from in vitro drug release was not 
subjected to the similarity factor analysis between marketed 
product and optimized formulation since the purpose of the target 
dissolution profile was to attain a slower release profile than the 
marketed formulation to achieve slow and extended-release [35, 36] 
RESULTS AND DISCUSSION 
Floating matrix tablets based on a floating agent in combination with 
the hydrogel polymers is one of the commonly used approaches to 
prepare floating delivery systems. Floating tablets which contained 
polymers and floating agent immersed in simulated gastric fluid 
demonstrated carbon dioxide generation and floating properties. MCC 
(avicel®PH 101) was incorporated as a filler excipient to maintain 
tablet weight constant. It also improves compressibility properties and 
has a very porous structure with this substance, more air would be 
present in the tablets and this could help the tablets to float. 
Additionally, this water-insoluble filler was incorporated also to 
counterbalance the faster solubility of the drug in the presence of the 
hydrophilic polymer and to provide a stable monolithic matrix. Also, 
sometimes release from a matrix made up of a high concentration of 
HPMC is incomplete and MCC addition could increase the release rate 
at a later stage. The presented formulation combination was also used 
by Buamgartener et al. (2000) for Pentoxyfiline and had found similar 
effect for floating dosage form. For gastro retentive drug delivery, it is 
essential to have short FLT and TFT in drug release, and accordingly, 
tablets were manufactured for controlling the drug release. 
Selection of floating agent 
Initial screening trials were fabricated with highly porous NE of 
calcium derivative, which allowed the manufacture of tablets with 
an inherently low density. The NE has recently introduced a porous 
microparticle with a nanostructured, lamellar surface. The 
inherently low apparent density of the NE (approx. 0.6g/cm3) 
enabled a mechanism of floatation. Due to its unique properties, it 
offers the possibility to compact tablets that can be further 
processed at a relative density<1. NE and citric acid (CA) were used 
as a gas-forming mixture. The CA is intended to provide an H+donor 
when contacted with gastric fluid which will evolve CO2 for flotation 
and also negate the effect of the difference in acidity in vivo. NE is 
carbonate salt hence generates CO2 in the presence of dissolution 
medium (0.1N HCl). The gas generated is trapped and protected 
within the gel formed by hydration of the polymer, thus decreasing 
the density of the tablet, and so the tablet becomes buoyant [37].  
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Selection of polymers 
Preliminary trials were fabricated by wet granulation using different 
grades of PEO as a swelling agent. The PEO matrix is a swellable and 
gel-forming complex made of drugs, PEO, and other excipients. PEO 
hydrates very fast and swells in the gastric fluid to a size that can be 
retained in the stomach even in the fed stage. It has a slippery 
characteristic that promotes retention of the tablet in the stomach in 
the fed state while gastric content tries to pass through pyloric 
sphincters. PEO alone may not help to sustain drug release for a 
longer duration. It rather necessitates the use of another polymer 
with higher gel strength to retain its matrix integrity. This is the 
reason why the use of other polymers such as HPMC along with PEO 
is required; stronger gel strength will result in the desired drug 
release rate and floating duration in the stomach. 
Selection of combination of polymers 
It is important to rationally select the appropriate polymers, to 
achieve the desirable floating behavior with strength and must be 
resistant to peristaltic force inside the stomach and remain floating 
for a reasonably long time. Additionally, the dosage form would act 
as a drug reservoir, releasing the drug slowly over a long time. In 
this context, the selection of the matrix polymer is of great 
importance. PEO swells rapidly but is unable to retain its swelling 
matrix for a longer period. Its rapid swelling helps to decrease the 
effective density of the gel matrix below 1 gm/ml, which is 
important for the floating of the system. MH is soluble in different 
media according to saturated solubility data. Therefore retardant 
must be incorporated in the formulation to sustain drug release. 
HPMC, a hydrophilic matrix acts as a retardant and can form a gel 
barrier to retard the drug release when it hydrates in the fluid. 
HPMC, on the other hand, provides integrity in the gel matrix when 
combined with PEO and helps to retard the drug release of a highly 
water-soluble drug-like MH. Rajanin Shakya et al., Wei He et al. has 
also found similar effect of HPMC K100M for Ofloxacin GFT and MH 
GFT, respectively. This is the reason why the combination of HPMC 
and PEO at 1:1 was selected for this study.  
To reduce the density of the tablets and improve the floating 
properties, a lipophilic excipient, stearyl alcohol was further added to 
the formulations. It has a relative density lower than 1, decrease the 
water intake, and improve the floating properties. The fatty excipient 
within the formulations could have also slowed down the penetration 
of the medium. It was observed that polymers in the matrix undergo 
simultaneous swelling, dissolution, and diffusion into the bulk 
medium, resulting in erosion and reduction of the matrix strength. It is 
also considered that the gas bubbles dissipating. 
Optimization trials using experimental D-optimal screening 
non-simplex mixture design 
Several formulation variables were considered towards the fulfillment of 
critical quality attributes. The preliminary study of the developed tablets 
without NE resulted in longer FLT (data not shown). Therefore, 
considering the importance of effervescence along with polymer 
swelling, NE act as a floating agent within the formulation. The level of 
the independent variables was selected based on the initial screening 
experiments followed by their observations (data not shown). The D-
optimal mixture design was used to optimize the GFT formulation. The 
peculiar characteristic of a mixture design is that the single components 
cannot be changed independently of one another since their sum must 
add up to 100%. This means that mixture factors are expressed as the 
fraction of the total amount and their experimental ranges lie between 0 
and 100%. In the present case, where the excipient mixture composition 
had to be optimized, the experimental range lay between 0 and 65.88% 
(w/w)-1120 mg since 1700 mg tablets were prepared with a constant 
drug content of 500 mg, citric acid 20 mg, stearyl alcohol 50 mg and 
magnesium stearate 10 mg corresponding to 580 mg: 34.12% (w/w) of 
the tablet weight.  
NE(X1), PEO(X2), and HPMC (X3) and MCC (X4) were chosen as the 
independent variables, as listed in table 3. FLT (Y1), TFT(Y2) and 
percentage of drug released in (dissolution) at 3h, 10h, and 24h (Y3, 
Y4, Y5) were chosen as response variables because they were 
considered as critical factors for floating sustained release dosage 
form to improve oral absorption of site-specific absorption drugs. 
  
Table 4: D-optimal screening design observed response values for different buoyant tablets 
Run order Dependant variables (Responses) 
  (FLT) (S) Y1  (TFT) (h) 
Y2 
Dissolution* 
3h drug release  
R3 (Y3) 
10h drug release  
R10 (Y4) 
24h drug release R24 (Y5) 
Run-1 240±8 22±0.2 43±0.31 69±0.54 101±0.88 
Run-2 105±7 23.7±0.3 44±0.33 70±0.57 100±0.77 
Run-3 94±5 24.6±0.3 46±0.41 69±0.71 101±0.91 
Run-4 65±7  18±0.3 59±0.52 79±0.70 101±0.87 
Run-5 55±7 26.5±0.4 35±0.28 65±0.59 96±0.73 
Run-6 90±8 25±0.7 48±0.42 72±0.70 100±0.77 
Run-7 200±14 27±0.5 36±0.31 64±0.57 94±0.71 
Run-8 75±8 22±0.4 43±0.42 69±0.71 100±0.92 
Run-9 185±11 16±0.5 58±0.48 79±0.73 100±0.59 
Run-10 180±13 22±0.5 42±0.40 69±0.58 100±0.50 
Run-11 50±5 22.2±0.7 41±0.39 68±0.57 100±0.82 
* Values are represented as mean of 3 
 
D-optimal non-simplex Screening design minimizes the determinant of 
the matrix of the independent variables. They are built algorithmically 
to provide the most accurate estimates of the model coefficients. 
Obtained response values of individual trial formulations were fitted 
inappropriate option of the software to find the best-fitted model. 
After due consideration, the best-fitted model for responses Y1, Y2, Y3, 
Y4, and Y5 was found to linear. This allowed the choice of the best 
model from the linear model based on the F-value derived from 
ANOVA, and the 2, predicted 2, and adjusted 2. The values of less 
than 0.05 were considered to be statistically significant. In cases of 
getting insignificance models (>0.05), the model reduction was 
performed to get a significant one. 
The statistic was applied to find out the mathematical relationships 
among independent variables with a particular response variable. 
The obtained results of MLRA analysis to find out the quantitative 
effects of independent variables on five response variables are 
provided in below equation 1 to 5. 
For FLT 
1/√ (FLT) = 0.1740*A+0.1188*B+0.0380*C+0.0694*D (Equation 1) 
For FT 
Floating time = 18.31*A+39.71*B+39.26*C+17.55*D (equation 2) 
For dissolution at 3h 
(Dissolution 3h)^1 = 56.18*A+1.50*B+8.25*C+56.63*D (equation 3) 
For dissolution at 10h 
Dissolution 10h= 77.52*A+43.77*B+46.02*C+77.52*D (equation 4) 
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For dissolution at 24h 
Dissolution 24h = 102.78*A+87.70*B+89.95*C+102.33*D (equation 5) 
From the above equations 1 to equation 5, it is evident that 
independent variables (first-order) have a positive effect for all five 
responses. On the other hand, higher-order terms have positive 
effects on all response variables. 
Analysis of variance (ANOVA) was the selected statistical test to 
ensure that the developed model was statistically significant (table 
5). Using a 5% significance level, a model was considered significant 
if the p-value (significance probability value) is less than 0.05. In 
table 6, individual models, including several important terms 
(marked in bold) were found to be less than 0.05. The nature of the 
interaction between independent variables to the response variables 
is qualitatively diagnosed by the respective sign of the coefficient 
representing individual independent variables and their 
combination in the equation; a positive sign indicates a synergistic 
effect while an antagonistic effect is represented by a negative one. 
 
Table 5: ANOVA summary results 




FLT 0.0001 0.4311 0.9779 0.9351 0.9684 26.3694 
TFT 0.0025 0.1324 0.8560 0.7130 0.7943 11.1427 
Dissolution 3 h (D3h) 0.0007 0.3070 0.9006 0.6945 0.8581 13.3228 
Dissolution 10 h (D10h) 0.0007 0.4223 0.8989 0.6913 0.8555 13.0730 
Dissolution 24 h (D24h) 0.0337 0.0988 0.6899 0.0427 0.5570 6.7812 
 
The selected model was significant since the p-value (significance 
probability value) is less than 0.05. The F value for FLT, TFT and 
D3,D10,D24 were found to be 103.28,13.87, 21.15,20.74, and 5.19 
respectively indicating that the models are significant. (Not shown in 
the table, taken from statease software). The response observations 
for FLT were found to be significant model terms. The lack of fit F 
values for FLT, TFT, D3,D10,D24 was found to be 0.4311, 0.1324, 
0.3070,0.4223, and 0.0988, respectively (table 5) suggesting that the 
lack of fit is significant. In all cases, the adjusted R2 values are in 
reasonable agreement with the predicted R2 values (0.9351 and 
0.9684 for FLT, 0.7130 and 0.7943 for TFT, 0.6945 and 0.8581for D 
3h, 0.6913 and 0.8555 for D10 h and 0.0427 and 0.5570 for D 24h). 
D24h R2 value is less due to close values of dissolution at 24h. In all 
the cases precision values were in the range 6–26 indicating an 
adequate signal and that the model can be used to navigate within 
the design space. 
FLT (Y1) 
Any floating dosage form should initiate floating immediately or 
after a minimum lag period to bypass the peristaltic movement and 
escape out from the stomach to the small intestine and in turn, helps 
in better drug absorption. 
Various formulation variables such as effects of concentration of NE, 
release modifying polymers (PEO and HPMC), and diluent (MCC) 
influenced the floating behavior of the present study. The floating 
tablets were composed of NE and citric acid as a floating agent and 
combination of PEO and HPMC as a swelling matrix. Upon contact with 
the acidic medium, i.e. 0.1 N HCl, the fluid permeates into the matrix 
and initiates an effervescence reaction. Liberated CO2 is entrapped 
within the polymeric network. Consequently, the polymer matrix 
swells rapidly and the swollen tablet achieves a required density, 
which initiates it to float, reaches on the surface, and remains buoyant 
for a long time as long as it maintains the required buoyancy.  
The effects of independent variables on FLT (Y1) are presented by 2-
D contour plots in fig. 1,2. FLT was found to be inversely related, not 
exactly proportional to the concentration of NE when the other two 
independent variables are present in equal proportion with 
changing concentration fig. 1, 2; however, from figures, it is evident 
that NE significantly influenced FLT with 400 mg produced the 
highest value of FLT. This value may be considered as a requirement 
for minimum effervescence to equilibrate gravitational force with 
buoyancy force exerted on the tablet while floating. The effect of 
polymers (B,C) on FLT, at a variable amount of NE (A), is also 
evident in fig. 2. As it is noticeable that the lower level of A and the 
entire range of D provide significant changes in FLT. In some 
formulation where HPMC concentration is more 250 mg/tab, the 
TFT is high, the reason may be HPMC could form gel barriers around 
the tablet after hydration, which slowed down further hydration of 
the tablet and retained the carbon dioxide inside the gel for a longer 
floating duration. Without the swollen gel, the carbon dioxide may 
leave the tablet more rapidly as the gastric contents move, leading to 
a relatively shorter floating duration, it was found that increasing 
the amount of HPMC could prolong both the FLT and the TFT, and 
decrease the rate of drug release. The results are in agreement with 
the findings of Veronika Eberle (2014) for Caffeine (highly water-
soluble drug) Gastro floating tablets, the difference being 
concentration of novel excipient used, which has been finalized 
based on suitability for studied formulation. 
 
 
Fig. 1: Trace plot for the response FLT using reference mixture 
 
 
Fig. 2: Three-dimensional response surface plot for the effect of 
the component indicating response FLT 
The above two fig. illustrate the effects of the component proportion 
change on the response FLT using a reference mixture. It is possible 
Pawar et al. 
Int J Pharm Pharm Sci, Vol 12, Issue 10, 62-71 
67 
 
to depict that the novel ingredient significantly reduces the FLT as 
the concentration increased. The MCC increases the FLT as the 
concentration increases. This effect could be explained by the point 
that NE exhibits a highly porous meshwork with a lamellar surface 
structure to interlock particles tightly, entrapped air in the porous 
FCC particles ensures low density of the tablet and provide 
floatation of the dosage form and tablet relative density<1. MCC 
causes delays in FLT due to an increase in the strength of the matrix 
tablets. 
Therefore, NE was proposed as an effective independent variable to 
get minimum floating lag time. The data demonstrate that NE, PEO, 
and HPMC affect the FLT. It may also be concluded that the low level 
of (amount of PEO and HPMC K100M) and the high level of NE 
causes short floating time and as the concentration of Polyox WSR 
303 and HPMC K100M increases, the density of the system increases 
and the FLT of the tablet increases. It may also occur due to the 
increasing hydrophilic nature of the polymer (PEO), allowing 
penetration of liquid through pores formed on the surface of the 
tablet due to PEO. 
Floating time (TFT) (Y2) 
The designed floating dosage form should maintain the buoyancy for 
a sufficient period. Long flotation maintained the dosage form in the 
upper GIT by prohibiting them from trans-locating to the lower GIT, 








Fig. 4: 3-D response surface plot for the effect of the 
components indicating response floating time 
The above two fig. illustrate the effects of the component proportion 
change on the response floating time using a reference mixture. It is 
possible to depict that the novel ingredient significantly reduces the 
floating time as the concentration increased. Compact density 
increased to slightly higher than 1 g/cm3 during floating time 
measurement in 0.1N HCl. The penetration of liquid into porous FCC 
particles was slowed down due to the gelation-layer formation of the 
polymer substances after contact with water. The observation is in 
agreement with Veronika in the patent (AU2013328718A1) when 
the pores are exposed to gastric fluid due to high concentration of 
excipient, water can enter the pores and fill them up and even 
propagate deep into the pores, particularly when the pores are 
interconnected due to the lamellar surface structure which interlock 
particles tightly. As a consequence, the inherent density will increase 
and that will decrease the floating capability of the tablet and thus 
provoking the sinking of tablets at a later stage. It is seen that as the 
amount of PEO and HPMC polymer increases, TFT also increases. It 
is increased due to swelling of the tablet, which keeps it intact for a 
longer period. 
The observations are in line with the Faria Senjoti et al. with respect to 
PEO WSR 303 and HPMC K100M, who had used MH as model drug. 
 
 




Fig. 6: 3-D response surface plot for the effect of the 
components indicating response dissolution at 3h 
 
The above two fig. illustrate the effects of the formulation change on 
the response dissolution at 3h. It is possible to depict that the novel 
ingredient and MCC significantly increases the dissolution as the 
concentration increased. The MCC increases the dissolution as the 
concentration increases due to porous nature and weakened matrix 
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due to the disintegrating nature of MCC. This effect could be 
explained by the point that NE exhibits a highly porous meshwork. 
The data demonstrate that NE, PEO, and HPMC affect the dissolution 
at 3h. It may also be concluded that the low level of (amount of PEO 
and HPMC K100M) and the high level of NE causes faster dissolution 
and as the concentration of polyox WSR 303 and HPMC K100M 
increases, the density of the system increases and dissolution of the 
tablet slows down. The high value of drug release at the initial 
period can be further explained by the high water solubility of MH. 
The rapid swelling and hydrophilic nature of PEO helps in rapid 
contact between drug (located near the periphery) and water. This 
might allow MH that is located at the outer surface of the tablets to 
get released quickly. The data demonstrate that NE, PEO, and HPMC 
affect the floating time. Based on the observations, it can be 
postulated that the novel ingredient and MCC significantly reduce 
the floating time as the concentration increased. The polymers 
increase the floating time as the concentration increases due to 
thicker hydrogel formation. 
Gharti et al. also found that similar behavior for Ranitidine, which is 
highly water-soluble drug. They have reported that at higher 
concentrations of HPMC K100M and the PEO the viscosity affects 
drug release. The result of the present study is also supported by 
those of the previous study by Gharti et al. 
 
Dissolution at 10h 
  
Fig. 7: Trace plot for the response dissolution at 10h using 
reference mixture 
Fig. 8: 3-D response surface plot for the effect of the components 
indicating response dissolution at 10h 
 
The above two fig. depict the effects of the formulation change on 
the response dissolution at 10h. It is possible to depict that the novel 
ingredient and MCC significantly increases the dissolution as the 
concentration increased. The MCC increases the dissolution as the 
concentration increases due to porous nature and weakened matrix, 
but it is slow as compared to 3h dissolution. The contribution of 
independent variables on dissolution was quite straight forward as 
detected by the two figures. 
The data demonstrate that all 4 independent variables affect the 
dissolution at 10h. It may also be inferred that as the concentration 
of PEO and HPMC K100M increases, the density of the system 
increases and the dissolution of the tablet slows down. The 
increased retardation is due to swelling of the tablet, which keeps it 
intact for a longer period. On contact with the dissolution medium, 
very hydrophilic and swelling nature of HPMC and PEO within the 
tablet causes the transformation to a gel-like structure. Viscous 
nature and thickness of gel determine the drug release. HPMC and 
PEO of higher viscosity grade are characterized by a slower 
hydration rate and by a stronger resistance to erosion compared to 
the corresponding polymers of lower viscosity.  
The swelling behavior of PEO is retained but balanced against the 
erosion behavior of HPMC K100M, which modulates the extent and 
progress of swelling. The gel layer formed by HPMC could also lengthen 
the diffusion path of drugs, realizing sustained release of Drugs. 
 
Dissolution at 24h  
 
 
Fig. 9:Trace plot for the response dissolution at 24h Fig. 10: 3-D response surface plot for the effect of the components 
indicating response dissolution at 24h 
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The above two fig. illustrate the effects of the factors on the 
response dissolution at 24h. It is possible to denote that the novel 
ingredient significantly reduces the FLT as the concentration 
increased. This has been attributed to greater extension or 
exercise of hydration and dissolution of the polymeric matrix as 
the drug release is subject to limitation. The increasing release 
restriction given by increasing PEO and HPMC proportions 
modifies the release mechanism from diffusion toward a 
relaxation and erosion controlled process. Every restriction of 
drug release is associated with an extended time of matrix 
exposition to dissolution medium to release a given quantity of the 
drug. It may also be concluded that the low level of (amount of 
PEO and HPMC K100M) and the high level of NE helps in attaining 
a faster extent of drug release i.e. close to 100%. 
 
Table 6: Constraints: to find out optimized solutions to achieve targeted dissolution profile 
Name Goal Lower Upper 
A: Novel Excipient is in range 400 600 
B: Polyethylene Oxide is in range 170 250 
C: HPMC is in range 170 250 
D: MCC is in range 20 380 
Floating lag time is in range 50 240 
Floating time is in range 23 27 
Dissolution 3h is target = 45 35 59 
Dissolution 10h is target = 70 64 79 
Dissolution 24h is target = 99 94 101 
 
Selection of the optimized formulation  
The point prediction option of the software was utilized to select the 
optimized formulation out of 11 trial formulations prepared according to 
D-optimal mixture design. The optimized composition of the present 
formulation was selected at the minimum values of Y1 and maximum 
value of Y2, whereas the defined value of Y3. After a thorough evaluation 
by the software, it was found that formulation F-2 with the NE (A) 500 
mg, PEO and HPMC(B, C) 210 mg and MCC(D) 200 mg is the optimized 
formulation. From this optimization study formulation batch, F-2 has 
followed criteria for optimized batch and has given desirable results, so 
formulation Batch F-2 is an optimized formulation. The results of this 
investigation show that the D-optimal mixture design for optimization 
and a mathematical model is suitable. 
The optimized formulation gave FLT, TFT, and dissolution at3h, 10h, 
and 24h, values of 105s, 23.7h and 45%, 77%, 100%, respectively. 
Drug release kinetics 
Drug dissolution from solid dosage forms has been described by 
kinetic models in which the dissolved amount of drug (Q) is a 
function of the test time (t). 
 
Table 9: Kinetic modeling of drug release 
Correlation coefficient values and kinetics of drug release based on dissolution profiles of MH tablets 
Code/Batch Zero-order First-order Higuchi Hixson crowell Korsmeyer peppas 
 R2 R2 R2 R2 R2 n 
Marketed formulation 0.1512 0.9921 0.8869 0.9703 0.9549 0.350 
Test formulation 0.4175 0.9447 0.9665 0.8916 0.9930 0.399 
 
In the present study, the dissolution data of marketed and test batch 
was fitted to first-order, Higuchi, zero-order, and Korsmeyer-peppas 
models. As clearly indicated in the above table values, both the 
formulations didn't follow zero-order release kinetics. The model 
that best fitted the release data was evaluated by the correlation 
coefficient (R2). The best fit with higher correlation (R2>0.98) was 
found with the Korsmeyer peppas equation for Test batch 
formulation and the first order for marketed formulation. The 
diffusion mechanism of drug release for test and the marketed 
formulation was further confirmed by Korsmeyer-peppas plots that 
showed fair linearity (R2 values between 0.95 and 0.99), with slope 
values less than 0.5, indicating that the drug release mechanism 
from the selected tablets was diffusion controlled. This finding was 
following other reported works. 
Comparison of optimized formulation F-2 with the marketed 
formulation  
The comparative in vitro dissolution study of F-2 and marketed 
formulation was shown in fig. 11. This study showed that the 
optimized formulation has a controlled release over 24h. Marketed 
formulation (carbophage XR 500 mg tablet) released the drug 90% in 
10h, whereas the prepared formulation F-2released only 70% at 10h. 
 
Table 10: Comparative release profile 
Time (h) Marketed batch* Test Batch 
0 0 0 
1 25 22 
2 41 37 
3 55 44 
4 60 53 
6 73 60 
8 81 66 
10 90 70 
12 99 75 
16 100 84 
20 100 92 
24 100 100 
* Result is presented as mean and number of times (n) =3 
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Fig. 11: Comparative release profile of marketed tablet vs test batch 
 
Evaluation parameters of drug and final formulation 
Fourier transforms infrared spectroscopy (FTIR) 
Interaction studies by FTIR spectroscopy were carried out and 
presented in the below table. FTIR spectrum of pure MH in fig. 12 
exhibits entire characteristic peak N-H stretching, C=N stretching, C-
N stretching, and C-H bending at 3367.66 cm-1, 1623.11 cm-1, 
1058.27 cm-1, and 1473.3 cm-1 respectively when compared with the 
reported reference spectrum of the drug. These distinctive drug 
peaks were present in the FTIR spectrum of optimized tablet 
formulation F-2. As the identical principle peaks were observed in 
all the cases, hence it shall be confirmed that interactions do not 




Fig. 12: Comparative FTIR spectra of drug and final tablet formulation 
 
CONCLUSION 
The NE, along with other polymers selected as the release modifiers, 
are more reliable as it released the drug slowly, extending the 
release over a longer period using D-optimal screening mixture 
design. PEO component of the matrix limits the initial release of the 
drug and imparts gastric retention through swelling, while the 
HPMC component lowers the amount of PEO required while still 
allowing the swelling to occur. Hence, using PEO and HPMC in 
combination would be beneficial in achieving prolonged gastro 
retention along with sustained delivery of highly soluble drugs like 
MH. It is noteworthy that NE has the potential for the development 
of a series of novel excipients for floating drug delivery systems. We 
have demonstrated that floating tablets based on NE with another 
polymer can efficiently control drug release in vitro. NE has 
markedly improved the floatation of the tablets in vitro and reduced 
process complexity as compared to the polymers commonly used 
now. Formulated tablets gave satisfactory results for TFT, FLT, and 
in vitro drug release. Moreover, the high swelling capacity of this 
polymer helped in maintaining the buoyancy with the minimal 
utilization of gas-evolving excipients such as citric acid. Formulated 
floating tablets best fitted to the Korsmeyer-Peppas model and 
diffusion-controlled mechanism. In the future, in vivo floating 
experiments and bioavailability tests will be carried out to prove 
there tention efficacy of floating systems based on novel excipient, 
which may eventually lead to promising applications to floating 
drug delivery systems. Therefore optimized formulation may 
become a logical way to improve the effectiveness of site-specific 
therapy against diabetes. However, there is further need for 
investigation for clinical acceptance of this novel drug delivery 
system.  
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